Trial Profile

Phase II Trial of Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
Focus Therapeutic Use

Most Recent Events

13 Apr 2023 Status changed from not stated to completed.
21 Jun 2020 Results (data cut-off February 2020, n=66) presented at the 25th Congress of the European Haematology Association
14 Jun 2020 According to a Celltrion media release, data from this study were presented as part of the Virtual Edition of the 25th EHA Annual Congress (EHA25 Virtual Congress).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com